Akhilesh Dubey
Research Subjects
Research Interests
Akhilesh Dubey has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Amitha Shetty
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutics, Mangalore, India
10 shared publicationsCynthia Lizzie Lobo
Nitte (Deemed to Be University), Department of Pharmaceutics NGSM Institute of Pharmaceutical Sciences (NGSMIPS) Mangalore Karnataka India
6 shared publicationsManohar Mahadev
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutics, Mangalore, India
6 shared publicationsSally A. El-Zahaby
Department of Pharmaceutics and Industrial Pharmacy, Pharm D Program, Egypt-Japan University of Science and Technology (E-JUST), Alexandria, Egypt
6 shared publications- Srinivas Hebbar
Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India
6 shared publications - Amitha Shetty
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutics, Mangalore 575018, India
5 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (46) , 59462-59481
Analytical quality-by-design-assisted RP-HPLC method for simultaneous determination of cinnamaldehyde and chrysin in a lipid-based delivery system and its greenness assessment
Chou-Talalay analysis identified a 1 : 1 CN : CR ratio. RP-HPLC simultaneously quantified CN and CR, and SNEDDS optimisation resulted in rapid self-emulsification, nanosized droplets, and improved bioaccessibility.
- 21 October 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (46) , 59462-59481
Open AccessAnalytical quality-by-design-assisted RP-HPLC method for simultaneous determination of cinnamaldehyde and chrysin in a lipid-based delivery system and its greenness assessment
Chou-Talalay analysis identified a 1 : 1 CN : CR ratio. RP-HPLC simultaneously quantified CN and CR, and SNEDDS optimisation resulted in rapid self-emulsification, nanosized droplets, and improved bioaccessibility.
- Open Access
- 16 October 2026
- Published by Manuscript Technomedia LLP in International Journal of Pharmaceutical Investigation
- Vol. 17 (1) , 138-149
A Systematic Review of the Regulatory Drug Approval Pathways in the European Medicine Agency and Other Regulated Markets
Regulatory agencies have developed expedited drug approval pathways to accelerate patient access to therapies addressing unmet medical needs, particularly in oncology and rare diseases. The European Medicines Agency (EMA) has introduced several such pathways; however, their efficiency compared to other global regulators remains a subject of evaluation. This systematic review aimed to evaluate regulatory drug approval pathways within the EMA and compare them with other regulated markets, focusing on innovation, review timelines, regulatory productivity, and clinical outcomes in high-need therapeutic areas. A comprehensive literature search was conducted across PubMed, Web of Science, and ScienceDirect databases covering studies published between 2015 and 2025. A total of 320 records were identified, of which 28 studies met the inclusion criteria after screening. Data extraction and methodological quality assessment were performed using the AMSTAR 2 checklist. The EMA provides multiple expedited pathways, including PRIME, Accelerated Assessment (A. As), Conditional Marketing Authorisation (CMA), and Exceptional Circumstances Approval. Despite these initiatives, their utilization remains lower compared to programs offered by the U.S. Food and Drug Administration (FDA). Median review timelines under EMA expedited pathways range from 315 to 476 days, which are longer than FDA timelines (175-192 days). Oncology drugs within EMA pathways experience accelerated progression, reducing development timelines by approximately 2.5 years. However, limited uptake of PRIME, extensive post-marketing obligations, annual renewal requirements (particularly for CMA), and administrative complexities contribute to delayed approvals relative to the U.S. EMA expedited pathways play a critical role in facilitating early access to innovative therapies while ensuring robust evidence generation and regulatory oversight. However, their overall effectiveness is constrained by longer review timelines and regulatory complexities. Greater harmonization of global regulatory frameworks and optimization of evidence requirements may enhance the efficiency and impact of accelerated approval pathways worldwide.
- 16 October 2026
- Published by Manuscript Technomedia LLP in International Journal of Pharmaceutical Investigation
- Vol. 17 (1) , 138-149
Open AccessA Systematic Review of the Regulatory Drug Approval Pathways in the European Medicine Agency and Other Regulated Markets
Regulatory agencies have developed expedited drug approval pathways to accelerate patient access to therapies addressing unmet medical needs, particularly in oncology and rare diseases. The European Medicines Agency (EMA) has introduced several such pathways; however, their efficiency compared to other global regulators remains a subject of evaluation. This systematic review aimed to evaluate regulatory drug approval pathways within the EMA and compare them with other regulated markets, focusing on innovation, review timelines, regulatory productivity, and clinical outcomes in high-need therapeutic areas. A comprehensive literature search was conducted across PubMed, Web of Science, and ScienceDirect databases covering studies published between 2015 and 2025. A total of 320 records were identified, of which 28 studies met the inclusion criteria after screening. Data extraction and methodological quality assessment were performed using the AMSTAR 2 checklist. The EMA provides multiple expedited pathways, including PRIME, Accelerated Assessment (A. As), Conditional Marketing Authorisation (CMA), and Exceptional Circumstances Approval. Despite these initiatives, their utilization remains lower compared to programs offered by the U.S. Food and Drug Administration (FDA). Median review timelines under EMA expedited pathways range from 315 to 476 days, which are longer than FDA timelines (175-192 days). Oncology drugs within EMA pathways experience accelerated progression, reducing development timelines by approximately 2.5 years. However, limited uptake of PRIME, extensive post-marketing obligations, annual renewal requirements (particularly for CMA), and administrative complexities contribute to delayed approvals relative to the U.S. EMA expedited pathways play a critical role in facilitating early access to innovative therapies while ensuring robust evidence generation and regulatory oversight. However, their overall effectiveness is constrained by longer review timelines and regulatory complexities. Greater harmonization of global regulatory frameworks and optimization of evidence requirements may enhance the efficiency and impact of accelerated approval pathways worldwide.
- Open Access
- 29 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1232
Phytosomal Delivery of Natural Bioactives: Advancing Bioavailability, Targeted Drug Delivery, and Clinical Translation
Natural bioactive compounds, especially plant-derived phytoconstituents, have gained significant interest due to their structural diversity, multitarget pharmacological activities, and favourable safety profiles. Their pharmaceutical translation is often hindered by poor aqueous solubility, limited membrane permeability, chemical instability, extensive first-pass metabolism, and, therefore, low oral bioavailability. Phytosomes, which are molecular complexes of bioactive compounds with phospholipids, have emerged as a new, effective, lipid-based delivery platform that can overcome these biopharmaceutical limitations and improve solubility, membrane interactions, systemic exposure, and therapeutic efficacy. The present review critically analyses recent advancements in phytosomal drug delivery, from formulation development to clinical translation, focusing on molecular complexation mechanisms, formulation strategies, physicochemical characterisation, pharmacokinetic enhancement, therapeutic applications, and challenges in clinical translation. The current review combines pharmaceutical design principles with recent advances in quality-by-design (QbD), computational formulation optimisation, hybrid phytosomal systems, scalable manufacturing approaches, and targeted delivery strategies. In addition, prospects for the future extension of phospholipid complexation to bioactive compounds from marine organisms, fungi, microorganisms, and algae are discussed in relevance to the next-generation natural product therapeutics. The present review serves as an emerging link between the discovery of natural bioactive compounds and the development of clinically translatable phytosomal systems from a pharmaceutical perspective.
- 29 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1232
Open AccessPhytosomal Delivery of Natural Bioactives: Advancing Bioavailability, Targeted Drug Delivery, and Clinical Translation
Natural bioactive compounds, especially plant-derived phytoconstituents, have gained significant interest due to their structural diversity, multitarget pharmacological activities, and favourable safety profiles. Their pharmaceutical translation is often hindered by poor aqueous solubility, limited membrane permeability, chemical instability, extensive first-pass metabolism, and, therefore, low oral bioavailability. Phytosomes, which are molecular complexes of bioactive compounds with phospholipids, have emerged as a new, effective, lipid-based delivery platform that can overcome these biopharmaceutical limitations and improve solubility, membrane interactions, systemic exposure, and therapeutic efficacy. The present review critically analyses recent advancements in phytosomal drug delivery, from formulation development to clinical translation, focusing on molecular complexation mechanisms, formulation strategies, physicochemical characterisation, pharmacokinetic enhancement, therapeutic applications, and challenges in clinical translation. The current review combines pharmaceutical design principles with recent advances in quality-by-design (QbD), computational formulation optimisation, hybrid phytosomal systems, scalable manufacturing approaches, and targeted delivery strategies. In addition, prospects for the future extension of phospholipid complexation to bioactive compounds from marine organisms, fungi, microorganisms, and algae are discussed in relevance to the next-generation natural product therapeutics. The present review serves as an emerging link between the discovery of natural bioactive compounds and the development of clinically translatable phytosomal systems from a pharmaceutical perspective.
- Open Access
- 7 September 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 98-107
Integrating Quality by Design and Design of Experiments for Scalable Nanoparticle Therapeutics: A Comprehensive Review
Nanoparticle-based drug delivery systems have tremendous advantages over the conventional dosage forms in terms of enhancing bioavailability, controlled release and tissue-specific targeting. However, despite great success at laboratory scale, the translation and commercialization of nanomedicines is still limited, mainly due to the inherent complexity of nanosystems, variability of the manufacturing processes and lack of globally unified regulatory frameworks. Integrating quality by design (QbD) with design of experiments (DoE) offers a scientific process for filling these gaps with more comprehensive formulation and understanding of processes. This review outlines QbD driven methodologies employed in the development of nanoparticles with a focus on the systematic determination of the quality target product profile (QTPP), critical quality attributes (CQAs), critical material attributes (CMAs), and critical process parameters (CPPs). The usefulness of DoEin screening and optimization methodology and multifactorial variables of formulation types is reviewed as a tool to derive robust design spaces and promote and provide predictive activity of nanoparticles such as particle size, polydispersity, drug loading, release kinetics, stability, etc. Updated knowledge about globally approved nanotechnology-based products is in the light of the rising clinical and regulatory acceptance of nanomedicine through various agencies. Additionally, the review summarizes key issues involving industrial implementation; from analytical limitations and barriers to the realization of the process on industrial scale, to stability issues and long-term safety evaluation; and emerging strategies including real-time monitoring, automation and advanced process control. By integrating QbD with DoE, industries can develop reproducible, efficient and scalable production processes for manufacturing nanoparticles.
- 7 September 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 98-107
Open AccessIntegrating Quality by Design and Design of Experiments for Scalable Nanoparticle Therapeutics: A Comprehensive Review
Nanoparticle-based drug delivery systems have tremendous advantages over the conventional dosage forms in terms of enhancing bioavailability, controlled release and tissue-specific targeting. However, despite great success at laboratory scale, the translation and commercialization of nanomedicines is still limited, mainly due to the inherent complexity of nanosystems, variability of the manufacturing processes and lack of globally unified regulatory frameworks. Integrating quality by design (QbD) with design of experiments (DoE) offers a scientific process for filling these gaps with more comprehensive formulation and understanding of processes. This review outlines QbD driven methodologies employed in the development of nanoparticles with a focus on the systematic determination of the quality target product profile (QTPP), critical quality attributes (CQAs), critical material attributes (CMAs), and critical process parameters (CPPs). The usefulness of DoEin screening and optimization methodology and multifactorial variables of formulation types is reviewed as a tool to derive robust design spaces and promote and provide predictive activity of nanoparticles such as particle size, polydispersity, drug loading, release kinetics, stability, etc. Updated knowledge about globally approved nanotechnology-based products is in the light of the rising clinical and regulatory acceptance of nanomedicine through various agencies. Additionally, the review summarizes key issues involving industrial implementation; from analytical limitations and barriers to the realization of the process on industrial scale, to stability issues and long-term safety evaluation; and emerging strategies including real-time monitoring, automation and advanced process control. By integrating QbD with DoE, industries can develop reproducible, efficient and scalable production processes for manufacturing nanoparticles.
- 31 May 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 32
Exploring the Potential of Dendrimers in Skin Drug Delivery: Applications and Advances
Dendrimers (DDs) have become a pioneering tool in dermatological nanomedicine thanks to their branched nanostructure, high precision, and multifunctional nature. The purpose of this review is to highlight the revolutionary potential of DDs regarding the primary barrier for skin drug delivery – the stratum corneum. The enhanced solubility, controlled drug release, and facilitated drug penetration achieved by the customized dendrimer architecture are described in terms of diffusion, degradation, and stimuli-responsive mechanisms. The latest achievements are critically assessed through the topical approaches for psoriasis, wound healing, and skin cancer treatment, as well as transdermal delivery for systemic vaccines and gene therapy. The essential aspect of surface engineering is also analyzed in terms of its dual-edged features—chemical functionalization optimizes skin affinity and therapeutic specificity while addressing toxicological issues. Quantitative data from the literature have been provided to support the benefits, such as a 4.5-fold increase in the transdermal flux of indomethacin using PAMAM G4 and 2.7-fold and 2.5-fold increases in the bioavailability of ketoprofen and diflunisal, respectively. Moreover, in the studies applying dendrimers combined with sonophoresis, the permeability results demonstrated a noticeable trend – e.g., 935.21 μg/cm2 versus 56.69 μg/cm2 permeation, which indicates the possibility of synergism with physical enhancement methods Moreover, in the studies applying dendrimers combined with sonophoresis, the permeability results demonstrated a noticeable trend – e.g., 935.21 μg/cm2 versus 56.69 μg/cm2 permeation, which indicates the possibility of synergism with physical enhancement methods. To ensure successful transfer to clinics, an increased focus on long-term safety, synthesis scalability, and reproducibility is needed. This article provides an in-depth, objective, and holistic assessment of dendrimers as a versatile, continually expanding and improving toolkit for targeted skin therapies.
- 31 May 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 32
Exploring the Potential of Dendrimers in Skin Drug Delivery: Applications and Advances
Dendrimers (DDs) have become a pioneering tool in dermatological nanomedicine thanks to their branched nanostructure, high precision, and multifunctional nature. The purpose of this review is to highlight the revolutionary potential of DDs regarding the primary barrier for skin drug delivery – the stratum corneum. The enhanced solubility, controlled drug release, and facilitated drug penetration achieved by the customized dendrimer architecture are described in terms of diffusion, degradation, and stimuli-responsive mechanisms. The latest achievements are critically assessed through the topical approaches for psoriasis, wound healing, and skin cancer treatment, as well as transdermal delivery for systemic vaccines and gene therapy. The essential aspect of surface engineering is also analyzed in terms of its dual-edged features—chemical functionalization optimizes skin affinity and therapeutic specificity while addressing toxicological issues. Quantitative data from the literature have been provided to support the benefits, such as a 4.5-fold increase in the transdermal flux of indomethacin using PAMAM G4 and 2.7-fold and 2.5-fold increases in the bioavailability of ketoprofen and diflunisal, respectively. Moreover, in the studies applying dendrimers combined with sonophoresis, the permeability results demonstrated a noticeable trend – e.g., 935.21 μg/cm2 versus 56.69 μg/cm2 permeation, which indicates the possibility of synergism with physical enhancement methods Moreover, in the studies applying dendrimers combined with sonophoresis, the permeability results demonstrated a noticeable trend – e.g., 935.21 μg/cm2 versus 56.69 μg/cm2 permeation, which indicates the possibility of synergism with physical enhancement methods. To ensure successful transfer to clinics, an increased focus on long-term safety, synthesis scalability, and reproducibility is needed. This article provides an in-depth, objective, and holistic assessment of dendrimers as a versatile, continually expanding and improving toolkit for targeted skin therapies.
- Open Access
- 22 March 2026
- Published by Springer Nature in Beni-Suef University Journal of Basic and Applied Sciences
- Vol. 15 (1) , 29
Network pharmacology and computational dissection of Solanum trilobatum bioactives reveals modulation of steroid receptor associated signalling in breast cancer
Background: Breast cancer is the most common form of malignancy in women worldwide. Although chemotherapy has been improved, the major drawbacks demand alternative treatment plans. Bioactives based on plants have become a key focus of interest as complementary agents and Solanum trilobatum has been known to possess multiple pharmacological activities that include, antioxidant, antimicrobial, anti-inflammatory, and anti-cancer effects. The molecular paths of action of its anticancer effect, however, is mostly unexplored. Methods: An integrative in silico strategy combining network pharmacology, molecular docking, molecular dynamics (MD) simulations, and binding free energy calculations was employed to elucidate the anticancer mechanisms of S. trilobatum bioactives. Phytoconstituents were mined from curated databases and screened based on drug-likeness, ADMET properties, and predicted anti-neoplastic activity. Protein protein interaction networks, KEGG pathway enrichment, and Gene Ontology analyses were performed to identify key pathways and hub genes. Selected bioactives were docked against oncogenic targets using AutoDock Vina and Schrödinger Glide. The most promising protein ligand complexes were further validated through long-timescale MD simulations and MMPBSA binding free energy analysis. Results: The enrichment of the analysis by KEGG pathways demonstrated the PI3K-Akt signalling pathway as the pathway that was massively altered. Network analysis identified AKT1, TP53, TNF, STAT3, MYC, IL6, HIF1A, EGFR, CTNNB1, and CASP3 as hub genes. Molecular docking of rheochrysin, hypoxiside, cytochalasin and 4- p- coumatoylquinic acid to oncogenic proteins, HRAS, KRAS, NCOA3 (a nuclear coactivator of steroid receptors), PGR, and PIK3CB oncogenes was observed using AutoDock 4.2 and Schrodinger Glide with binding affinities displaying strong binding. Molecular dynamics simulations further confirmed stable and sustained interactions, particularly between KRAS–4-p-coumaroylquinic acid and TP53–Hypoxoside A complexes. Conclusion: These findings provide mechanistic insights into the anticancer potential of S. trilobatum , supporting its role as a promising source of bioactive compounds capable of modulating steroid receptor–associated signalling networks in breast cancer therapy. Graphic
- 22 March 2026
- Published by Springer Nature in Beni-Suef University Journal of Basic and Applied Sciences
- Vol. 15 (1) , 29
Open AccessNetwork pharmacology and computational dissection of Solanum trilobatum bioactives reveals modulation of steroid receptor associated signalling in breast cancer
Background: Breast cancer is the most common form of malignancy in women worldwide. Although chemotherapy has been improved, the major drawbacks demand alternative treatment plans. Bioactives based on plants have become a key focus of interest as complementary agents and Solanum trilobatum has been known to possess multiple pharmacological activities that include, antioxidant, antimicrobial, anti-inflammatory, and anti-cancer effects. The molecular paths of action of its anticancer effect, however, is mostly unexplored. Methods: An integrative in silico strategy combining network pharmacology, molecular docking, molecular dynamics (MD) simulations, and binding free energy calculations was employed to elucidate the anticancer mechanisms of S. trilobatum bioactives. Phytoconstituents were mined from curated databases and screened based on drug-likeness, ADMET properties, and predicted anti-neoplastic activity. Protein protein interaction networks, KEGG pathway enrichment, and Gene Ontology analyses were performed to identify key pathways and hub genes. Selected bioactives were docked against oncogenic targets using AutoDock Vina and Schrödinger Glide. The most promising protein ligand complexes were further validated through long-timescale MD simulations and MMPBSA binding free energy analysis. Results: The enrichment of the analysis by KEGG pathways demonstrated the PI3K-Akt signalling pathway as the pathway that was massively altered. Network analysis identified AKT1, TP53, TNF, STAT3, MYC, IL6, HIF1A, EGFR, CTNNB1, and CASP3 as hub genes. Molecular docking of rheochrysin, hypoxiside, cytochalasin and 4- p- coumatoylquinic acid to oncogenic proteins, HRAS, KRAS, NCOA3 (a nuclear coactivator of steroid receptors), PGR, and PIK3CB oncogenes was observed using AutoDock 4.2 and Schrodinger Glide with binding affinities displaying strong binding. Molecular dynamics simulations further confirmed stable and sustained interactions, particularly between KRAS–4-p-coumaroylquinic acid and TP53–Hypoxoside A complexes. Conclusion: These findings provide mechanistic insights into the anticancer potential of S. trilobatum , supporting its role as a promising source of bioactive compounds capable of modulating steroid receptor–associated signalling networks in breast cancer therapy. Graphic
- 27 February 2026
- Published by Wiley in Biomedical Chromatography
- Vol. 40 (4) , e70393
Quality by Design–Based RP‐HPLC Method for Simultaneous Estimation of 4‐Hydroxytamoxifen and Thymoquinone in Liposomal Formulation
Developing a method for the simultaneous quantification of drugs in combination formulations is crucial for optimizing combination therapy. 4‐Hydroxytamoxifen (4‐OHT) and thymoquinone exhibit synergistic activity in breast cancer treatment, yet no robust analytical method exists for their simultaneous estimation in liposomal systems. This study aimed to design, optimize and validate an RP‐HPLC method for quantifying both drugs using an analytical quality by design (AQbD) approach. An analytical target profile (ATP) was defined, and risk assessment using an Ishikawa diagram identified mobile phase composition, flow rate and column temperature as critical parameters. Method optimization was performed using a Box–Behnken Design, evaluating effects on retention times, peak areas, tailing factors and resolution. Optimal conditions included a 90:10 methanol:aqueous mobile phase, 0.5 mL/min flow rate and 35°C column temperature. The method was validated per ICH Q2(R1) guidelines, demonstrating excellent sensitivity (LOD 0.69–0.29 μg/mL), accuracy (95%–105% recovery) and precision (RSD < 2%). The method was successfully applied for drug estimation in liposomal formulations, ex vivo permeation, cytotoxicity and cellular uptake studies. Liposomal gels showed high entrapment efficiency, enhanced drug release, permeation and cellular uptake. Analytical Eco‐Scale assessment confirmed excellent green performance.
- 27 February 2026
- Published by Wiley in Biomedical Chromatography
- Vol. 40 (4) , e70393
Quality by Design–Based RP‐HPLC Method for Simultaneous Estimation of 4‐Hydroxytamoxifen and Thymoquinone in Liposomal Formulation
Developing a method for the simultaneous quantification of drugs in combination formulations is crucial for optimizing combination therapy. 4‐Hydroxytamoxifen (4‐OHT) and thymoquinone exhibit synergistic activity in breast cancer treatment, yet no robust analytical method exists for their simultaneous estimation in liposomal systems. This study aimed to design, optimize and validate an RP‐HPLC method for quantifying both drugs using an analytical quality by design (AQbD) approach. An analytical target profile (ATP) was defined, and risk assessment using an Ishikawa diagram identified mobile phase composition, flow rate and column temperature as critical parameters. Method optimization was performed using a Box–Behnken Design, evaluating effects on retention times, peak areas, tailing factors and resolution. Optimal conditions included a 90:10 methanol:aqueous mobile phase, 0.5 mL/min flow rate and 35°C column temperature. The method was validated per ICH Q2(R1) guidelines, demonstrating excellent sensitivity (LOD 0.69–0.29 μg/mL), accuracy (95%–105% recovery) and precision (RSD < 2%). The method was successfully applied for drug estimation in liposomal formulations, ex vivo permeation, cytotoxicity and cellular uptake studies. Liposomal gels showed high entrapment efficiency, enhanced drug release, permeation and cellular uptake. Analytical Eco‐Scale assessment confirmed excellent green performance.
- Open Access
- 18 February 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Exploiting the role of milk extracellular vesicles: a comprehensive analysis on isolation methods, characterization, surface modifications, and their therapeutic applications
Milk EVs (MEVs) are a class of extracellular vesicles (EVs) that have attracted significant attention for their potential as natural nanocarriers in drug delivery. These nanosized vesicles (30 - 150 nm) are composed of a lipid bilayer that encapsulates proteins, nucleic acids, and lipids. The biogenesis of EVs involves a tightly regulated “endocytosis-fusion-secretion” pathway, and they are secreted by diverse cells into physiological fluids (blood, urine, and saliva). The isolation and characterization methods of MEVs are essential to achieve high purity, structural integrity, size distribution, and biomolecular composition. Efficient drug loading strategies such as passive diffusion, electroporation, and sonication enable the incorporation of therapeutic molecules. Surface modifications such as PEGylation, ligand conjugation, and genetic engineering further enhance the targeting efficiency, circulation stability, and therapeutic efficacy. Given their biocompatibility, low immunogenicity, and natural ability to traverse biological barriers, MEVs offer a scalable, and non-toxic platform for targeted drug delivery such as span cancer therapy, neurodegenerative disease treatment, and immune modulation. However, further research is needed to optimize MEV-based therapeutics, ensuring their efficacy and safety through rigorous clinical trials. This review explores the biogenesis, composition, isolation, characterization, drug-loading strategies, surface modifications, and therapeutic applications of MEVs, highlighting their emerging role in nanomedicine. Graphical abstract
- 18 February 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessExploiting the role of milk extracellular vesicles: a comprehensive analysis on isolation methods, characterization, surface modifications, and their therapeutic applications
Milk EVs (MEVs) are a class of extracellular vesicles (EVs) that have attracted significant attention for their potential as natural nanocarriers in drug delivery. These nanosized vesicles (30 - 150 nm) are composed of a lipid bilayer that encapsulates proteins, nucleic acids, and lipids. The biogenesis of EVs involves a tightly regulated “endocytosis-fusion-secretion” pathway, and they are secreted by diverse cells into physiological fluids (blood, urine, and saliva). The isolation and characterization methods of MEVs are essential to achieve high purity, structural integrity, size distribution, and biomolecular composition. Efficient drug loading strategies such as passive diffusion, electroporation, and sonication enable the incorporation of therapeutic molecules. Surface modifications such as PEGylation, ligand conjugation, and genetic engineering further enhance the targeting efficiency, circulation stability, and therapeutic efficacy. Given their biocompatibility, low immunogenicity, and natural ability to traverse biological barriers, MEVs offer a scalable, and non-toxic platform for targeted drug delivery such as span cancer therapy, neurodegenerative disease treatment, and immune modulation. However, further research is needed to optimize MEV-based therapeutics, ensuring their efficacy and safety through rigorous clinical trials. This review explores the biogenesis, composition, isolation, characterization, drug-loading strategies, surface modifications, and therapeutic applications of MEVs, highlighting their emerging role in nanomedicine. Graphical abstract
- Open Access
- 7 September 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 1-8
FAST-TRACKING DRUG APPROVALS: A SYSTEMATIC REVIEW OF THE US FDA'S EXPEDITED REGULATORY PATHWAYS
The current review explores the utilization and impact of the United States Food and Drug Administration’s (US-FDA) accelerated drug approval pathways over the past decade (2014–2024). Specifically, it evaluates five key programs: Orphan Drug Designation, Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval. The primary aim is to assess how these expedited pathways influence drug development timelines and overall approval success rates. A comprehensive literature search was conducted using databases such as PubMed, Scopus, Web of Science, and Google Scholar. The search yielded 200 articles, of which 110 met the inclusion criteria. From these, 25 key studies were selected for detailed analysis. The findings indicate that Priority Review accounted for the highest number of drug approvals (367 approvals, 55%), followed by Orphan Drug Designation (279 approvals, 42%) and Fast Track (215 approvals, 32%). Breakthrough Therapy and Accelerated Approval contributed to 124 (19%) and 103 (15%) approvals, respectively. These programs have significantly accelerated the availability of essential treatments, particularly in oncology and rare diseases. However, challenges persist. The reliance on surrogate endpoints raises concerns about long-term efficacy, and the need for rigorous post-marketing surveillance remains critical to ensure safety and therapeutic value. In conclusion, the increasing adoption of these accelerated pathways underscores their growing importance in meeting urgent medical needs. While they offer promising benefits in terms of faster access to life-saving therapies, a balanced approach that ensures thorough evaluation and long-term monitoring is essential for sustained public health outcomes.
- 7 September 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 1-8
Open AccessFAST-TRACKING DRUG APPROVALS: A SYSTEMATIC REVIEW OF THE US FDA'S EXPEDITED REGULATORY PATHWAYS
The current review explores the utilization and impact of the United States Food and Drug Administration’s (US-FDA) accelerated drug approval pathways over the past decade (2014–2024). Specifically, it evaluates five key programs: Orphan Drug Designation, Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval. The primary aim is to assess how these expedited pathways influence drug development timelines and overall approval success rates. A comprehensive literature search was conducted using databases such as PubMed, Scopus, Web of Science, and Google Scholar. The search yielded 200 articles, of which 110 met the inclusion criteria. From these, 25 key studies were selected for detailed analysis. The findings indicate that Priority Review accounted for the highest number of drug approvals (367 approvals, 55%), followed by Orphan Drug Designation (279 approvals, 42%) and Fast Track (215 approvals, 32%). Breakthrough Therapy and Accelerated Approval contributed to 124 (19%) and 103 (15%) approvals, respectively. These programs have significantly accelerated the availability of essential treatments, particularly in oncology and rare diseases. However, challenges persist. The reliance on surrogate endpoints raises concerns about long-term efficacy, and the need for rigorous post-marketing surveillance remains critical to ensure safety and therapeutic value. In conclusion, the increasing adoption of these accelerated pathways underscores their growing importance in meeting urgent medical needs. While they offer promising benefits in terms of faster access to life-saving therapies, a balanced approach that ensures thorough evaluation and long-term monitoring is essential for sustained public health outcomes.